BioCentury
ARTICLE | Clinical News

Aduro pancreatic cancer combo fails Phase IIb test

May 17, 2016 1:11 AM UTC

Aduro Biotech Inc. (NASDAQ:ADRO) fell $1.78 (17%) to $8.91 on Monday after it said a combination of CRS-207 and GVAX Pancreas cancer vaccine missed the primary overall survival (OS) endpoint in the Phase IIb ECLIPSE study to treat patients with metastatic pancreatic cancer who had failed at least two prior therapies.

The 303-patient, open-label study compared the combo plus low-dose cyclophosphamide vs. chemotherapy or CRS-207 as monotherapy. Aduro said median OS was 3.8 months for patients receiving the combo vs. 4.6 months for chemotherapy and 5.4 months for CRS-207 monotherapy. ...